Acne patients may have significant quality-of-life (QoL) impairment, therefore assessment of health-related QoL (HRQoL) in acne patients is recommended by several national and international guidelines as an integral part of acne management. The inclusion of QoL assessment in core outcome sets is now a popular idea. Several acne-specific QoL questionnaires are available but none cover all topics presented in other instruments. The impact of acne on different aspects of QoL may vary between patients from different age groups. The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes has initiated a study on the relevance of the different QoL topics in acne patients. Detailed recommendations on treatment goals and changes of treatment approaches based on a validated banding system and a minimal clinically important difference in HRQoL questionnaires (such as the Dermatology Life Quality Index) may be an important and promising approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40257-019-00438-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-COVID-19 Syndrome-associated Risk Factors for Acne Exacerbation.
Curr Med Chem
December 2024
Department of Dermatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Introduction: This study aimed to investigate the impact of coronavirus disease 2019 (COVID-19) syndrome on various aspects of acne exacerbation. Additionally, we aimed to explore the risk factors for acne exacerbation after COVID-19 syndrome.
Method: A total of 211 subjects with acne were enrolled, and their key demographic characteristics and lifestyle factors were recorded.
Recalcitrant Pustular Dermatosis Successfully Treated With Prolonged Isotretinoin Therapy.
Cureus
November 2024
Dermatology, Imperial Dermatology, Hollywood, USA.
Isotretinoin (13-cis-retinoic acid) is a well-established systemic treatment for moderate to severe acne vulgaris, renowned for its ability to target multiple contributors to acne pathogenesis. However, its therapeutic potential extends beyond conventional acne management. This case report highlights its efficacy in treating recalcitrant pustular dermatosis, a condition that proved resistant to standard therapies and posed significant diagnostic challenges.
View Article and Find Full Text PDFResponse to Fleshner et al., "Bridging the Gap in Acne Vulgaris Research for Skin of Color Patients: Response to: "Assessing the Inclusion of Post-Inflammatory Hyperpigmentation Outcomes in Acne Vulgaris Clinical Trials".
J Am Acad Dermatol
December 2024
Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York, USA 10016. Electronic address:
Bridging the Gap in Acne Vulgaris Research for Skin of Color Patients.
J Am Acad Dermatol
December 2024
Department of Dermatology, Weill Cornell Medicine, New York, NY, USA. Electronic address:
Efficacy of a 2-MNG-Containing Depigmenting Serum in the Treatment of Post-Inflammatory Hyperpigmentation.
J Cosmet Dermatol
December 2024
La Roche Posay Laboratoire Dermatologique, Levallois-Perret, France.
Background: Post-inflammatory hyperpigmentation (PIHP) predominantly affects patients with melanin-rich skin, significantly impacting them psychosocially due to more frequent and severe pigmentary changes. In this study, the efficacy of a novel depigmenting agent 2-mercaptonicotinoyl glycine (Melasyl) in a dermocosmetic (DC) serum formulation is assessed as a stand-alone treatment of PIHP without sunscreen.
Materials And Methods: Thirty-two Mauritian subjects aged 18-50 years of phototype IV-VI presenting mild acne (GEA2) and moderate to severe PIHP (PAHPI > 10) participated in this study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!